Rates still elevated and growth risk looms; tech gets punished first. If the Fed stays sticky, $META probably bounces, then retests again.
Feels like the crowd keeps chasing hype and then blames the crowd when it bleeds. If $META's cash runway and ad metrics aren't broken, why assume a 50% selloff is terminal? Feels like FOMO and fear trading.
Feels like the market keeps rewarding hype over execution. Pipeline rumors spike prices, then reality hits. Not convinced regulators will be kind to these late-stage candidates.
NVAX’s 12-month run rate is 15%—not great.
Kinda nervous about biotech hype right now.
Hard to buy the dip when rates stay higher-for-longer and growth risk is elevated. If NVDA keeps bleeding relative to QQQ, it's not a rotation story but a macro weakness signal.
Trend's down; I'm riding the red until it flips.
Anyone else feeling whiplash after that red candle?
He’s basically saying: “I’m leaning tech-heavy, but not all-in. Diversified across growth and broad market.” Feels cautious yet bullish.
Semis still spooking me; margins look fragile.
Everyone’s cheering the tech tilt, but I’m noticing he’s underweight cyclicals and cash. If earnings fade, that overweight SPY/QQQ sleeve could drag him down more than a laggard semis position.
